Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.39 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
| ▸ | KDM6B | O15054 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706197 | 0.91 | CYP1A2 (0.42) | LMNAVCAM1CYP1A2CYP2C9HIF1A | |
| SCHEMBL2886933 | 0.88 | TSHR (0.47) | LMNAVCAM1CYP1A2CYP2C9HIF1A | |
| SCHEMBL2885765 | 0.78 | ALDH1A1 (0.46) | LMNACYP1A2CYP2C9HIF1AALDH1A1 | |
| SCHEMBL11233782 | 0.77 | CYP1A2 (0.42) | CYP1A2CYP2C9HIF1A | |
| SCHEMBL2597460 | 0.75 | CYP1A2 (0.41) | CYP1A2CYP2C9HIF1ATSHR | |
| SCHEMBL13705616 | 0.74 | EGLN1 (0.43) | LMNAEGLN1ALKBH5SUCNR1KDM6B | |
| SCHEMBL2885833 | 0.73 | HIF1A (0.44) | LMNACYP1A2CYP2C9HIF1AALDH1A1 | |
| SCHEMBL414238 | 0.72 | DGKA (0.50) | LMNAALDH1A1MAPTKMT2AMAPK1 | |
| SCHEMBL11573013 | 0.71 | MCL1 (0.52) | LMNAEGLN1ALKBH5SUCNR1MCL1 | |
| SCHEMBL3504478 | 0.71 | CYP1A2 (0.34) | CYP1A2CYP2C9HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261890-A1 | METHOD FOR THE CHEMICAL SYNTHESIS OF OLIGONUCLEOTIDES | VARGEESE CHANDRA | 2010-10-14 | — | — | US | claimed |
| US-7777023-B2 | Method for the chemical synthesis of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2010-08-17 | — | — | US | claimed |
| US-20100261890-A1 | METHOD FOR THE CHEMICAL SYNTHESIS OF OLIGONUCLEOTIDES | VARGEESE CHANDRA | 2010-10-14 | — | — | US | disclosed |
| US-7777023-B2 | Method for the chemical synthesis of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7205399-B1 | Methods and reagents for oligonucleotide synthesis | SIRNA THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20060036090-A1 | Method for the chemical synthesis of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| US-6995259-B1 | Method for the chemical synthesis of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20040215010-A1 | Universal solid supports for solid phase oligosynthesis and methods for their preparation and use | PROLIGO, LLC | 2004-10-28 | — | — | US | disclosed |
| EP-1289911-A2 | UNIVERSAL SOLID SUPPORTS FOR SOLID PHASE OLIGOSYNTHESIS AND METHODS FOR THEIR PREPARATION AND USE | Proligo LLC (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096357-A2 | UNIVERSAL SOLID SUPPORTS FOR SOLID PHASE OLIGOSYNTHESIS AND METHODS FOR THEIR PREPARATION AND USE | PROLIGO LLC (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-1990003381-A1 | METHOD OF SYNTHESIS OF ALPHA OLIGORIBONUCLEOTIDES AND COMPOUNDS USEFUL FOR THE METHOD | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1990-04-05 | — | — | WO | disclosed |
| EP-0360626-A1 | Process for the synthesis of alpha-oligoribonucleotides, and components useful in the process | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1990-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036090-A1 | Method for the chemical synthesis of oligonucleotides | RNGTT, NSUN3, NSUN2 | LMNA 1022/4885EGLN1 4266/4885ALKBH5 177/4885 |
| US-20100261890-A1 | METHOD FOR THE CHEMICAL SYNTHESIS OF OLIGONUCLEOTIDES | RNGTT, NSUN3, NSUN2 | LMNA 1022/4885EGLN1 4266/4885ALKBH5 177/4885 |
| US-20040215010-A1 | Universal solid supports for solid phase oligosynthesis and methods for their preparation and use | POLRMT, POLR2H, POLL | LMNA 3761/4885EGLN1 4104/4885ALKBH5 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.